MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
ITEM 7.01
|
REGULATION FD DISCLOSURE.
|
On April 7, 2017, MabVax Therapeutics Holdings, Inc. (the
Company) updated and made available its scientific presentation.
The scientific presentation is attached hereto as Exhibit 99.1.
Company) updated and made available its scientific presentation.
The scientific presentation is attached hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d)Exhibits.
The exhibit listed in the following Exhibit Index is furnished
with this Current Report on Form 8-K.
with this Current Report on Form 8-K.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Power Point Scientific Presentation dated April 7, 2017
|
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Recent Trading Information
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) closed its last trading session down -0.04 at 2.08 with 18,032 shares trading hands.
